A road less traveled paved by IDO silencing

Orchestrating a cytotoxic polymorphonuclear neutrophil (PMN) response strictly focused within the tumor tissue remains a formidable challenge for the successful therapeutic use of these cells. A Salmonella vector carrying an shRNA against indoleamine 2,3-dioxygenase has been shown to recruit PMNs and enhance their activation specifically in the tumor bed, resulting in significant anticancer effects.

[1]  B. Blazar,et al.  Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. , 2012, Cancer research.

[2]  J. Sampson,et al.  Regulatory T Cells Move in When Gliomas Say “I DO” , 2012, Clinical Cancer Research.

[3]  Atique U. Ahmed,et al.  IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival , 2012, Clinical Cancer Research.

[4]  R. Muschel,et al.  On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. , 2012, Critical reviews in oncology/hematology.

[5]  M. Hensel,et al.  Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. , 2011, Cancer research.

[6]  G. Cheng,et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.

[7]  D. Munn,et al.  Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. , 2009, Blood.

[8]  H. Kajiyama,et al.  Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival , 2008, Clinical Cancer Research.

[9]  C. MacKenzie,et al.  Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines. , 2007, Current drug metabolism.

[10]  P. Carey,et al.  Neutrophil activation, vascular leak toxicity, and cytolysis during interleukin-2 infusion in human cancer. , 1997, Surgery.